read more

first_img Technology | Contrast Media | July 15, 2019 FDA Approves Bayer’s Gadavist Contrast for Cardiac MRI in Adult Coronary Artery Disease Patients The U.S. Food and Drug Administration (FDA) has approved Gadavist injection for use in cardiac magnetic resonance… read more News | Radiopharmaceuticals and Tracers | July 26, 2019 NorthStar Medical Radioisotopes Awarded $30 Million by U.S. Department of Energy NorthStar Medical Radioisotopes LLC has been awarded $15 million in a cooperative agreement with the U.S. Department of… read more Feature | Contrast Media | July 18, 2019 | By Greg Freiherr How To Manage Risk in the MR Suite Macrocyclic contrast agents have the best safety profile of all the magnetic resonance (MR) contrast media that are n read more FacebookTwitterLinkedInPrint分享 News | Interventional Radiology | July 31, 2019 International Multidisciplinary Group Publishes Recommendations for Personalized HCC Treatment With Y90 TheraSphere New consensus recommendations for personalized treatment for hepatocellular carcinoma (HCC) with BTG’s TheraSphere have… read more Technology | Contrast Media | August 05, 2019 Bracco Receives FDA Approval for Varibar Thin Liquid for Oral Suspension Bracco Diagnostics Inc. announced U.S. Food and Drug Administration (FDA) approval for Varibar Thin Liquid (barium… read more News | Radiopharmaceuticals and Tracers | August 02, 2019 ASRT Supports Radiopharmaceutical Reimbursement Bill The American Society of Radiologic Technologists (ASRT) announced its support for House Resolution (HR) 3772, a measure… read more News | Radiopharmaceuticals and Tracers | July 16, 2019 NorthStar Medical Radioisotopes Completes Construction on Beloit, Wis. Molybdenum-99 Processing Facility NorthStar Medical Radioisotopes LLC  announced completion of construction on its 20,000-square-foot molybdenum-99 (Mo-… read more News | January 30, 2015 Lantheus Medical Imaging Announces Xenon 133 Supply Agreement with Institute for Radioelements Agreement demonstrates commitment to secure continuous supply of Xenon 133 to U.S. medical market through 2016 and beyond Image courtesy of LantheusJanuary 30, 2015 — Lantheus Medical Imaging Inc. announced an agreement with the Institute for Radioelements (IRE) for the future supply of Xenon Xe 133 Gas (Xenon 133). Currently, Lantheus is the only U.S. manufacturer of Xenon 133, which is an inhaled radiopharmaceutical imaging agent used for the evaluation of pulmonary function and for imaging the lungs, as well as the assessment of cerebral blood flow.  Under the terms of the agreement, IRE will provide bulk Xenon 133 to Lantheus for processing and finishing, once development work has been completed and all necessary regulatory approvals have been obtained. Lantheus estimates commercial production will occur in 2016.For more information: www.lantheus.com, www.ire.eu Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco News | PET-CT | August 15, 2019 United Imaging Announces First U.S. Clinical Installation of uExplorer Total-body PET/CT United Imaging announced that its uExplorer total-body positron emission tomography/computed tomography (PET/CT) system… read more Related Content News | Cardiovascular Ultrasound | August 07, 2019 Contrast Use in First Transthoracic Echocardiogram for Heart Failure Reduces Repeat Testing Heart failure is the fourth most common cause for all admission to U.S. hospitals, and it is the most common reason for… read more News | Radiopharmaceuticals and Tracers | July 01, 2019 Bracco Imaging Acquires Blue Earth Diagnostics Bracco Imaging S.p.A. has signed a definitive agreement to acquire Blue Earth Diagnostics, a molecular imaging company… read morelast_img

Leave a Reply

Your email address will not be published. Required fields are marked *